(Date:7/4/2009)...ent pain and injury, doctors say , , SAT...rs are not as young as they used to be, exercise i...ns are in order to stay injury-free. , "As b...t themselves from injuries when exercising," Dr. R...Orthopaedic Surgeons, said in a news release. "A l...
(Date:7/3/2009)...on in microbiology testing walks on four legs and ...e version of the familiar woolly barnyard resident...of Medicine, which is to be published July 3 in P...low-maintenance and parasite-resistant, they,re al... necessary to diagnose infectious disease in the d...
(Date:7/3/2009)...e/ -- Bertalan Mesko, medical blogger and health 2...dical professionals focusing on how the virtual wo...are expensive and patients are also open to use vi...ctors enter a virtual realm and organize medical p...provides opportunities for case presentations, e-l...
(Date:7/3/2009)...ll lead to treatments, , , FRIDAY, July...ve found a major cellular flaw that may drive the ...ught early, lung cancer can often be treated. But ...ell advanced. Though doctors can sometimes put the...back more virulent than ever, frequently spreading...
Breaking Medicine News(10 mins):Health News:Exercise Tips to Keep Boomers on Their Feet 2Health News:Rare sheep could be key to better diagnostic tests in developing world, says Stanford study 2Health News:Rare sheep could be key to better diagnostic tests in developing world, says Stanford study 3Health News:Cell Pathway May Be Key to Lung Cancer's Spread 2Health News:Cell Pathway May Be Key to Lung Cancer's Spread 3The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications.
Unipolar temporary atrial pacing lead is smaller and thinner than Medtronics standard temporary pacing leads. It is well suited for thin, delicate, atrial tissue.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
Medicine Products:
(Date:7/1/2009)...KJAVIK, Iceland, July 1 ...a ever undertaken has revealed several new common,...an genome (SNPs) linked to,risk of the disease. T...sts,led by a team from deCODE genetics (Nasdaq: ...patients and control participants from fourteen co...
(Date:6/30/2009)...GO, June 30 Accumetrics, Inc. anno...patients) in the enrollment of its landmark clinic...h A V erifyNow(R) Assay I mpact on T hrombosis ...ed to demonstrate the value of providing clinician... poor responders to clopidogrel (Plavix(R)). The ...
(Date:6/29/2009)...tive Study Seeks to Assess RSV Burden in Outpatien...ommitment to Pediatric Research , , GAITHERSB...ues to advance its commitment to pediatric researc...onal prospective study designed to assess the burd...erm infants 32-to-35 weeks gestational age (GA) in...
(Date:6/29/2009)...THAMPTON, England, June 29 Vantia ...developing novel, small molecule drugs,targeting ...tive results from,a Phase IIa clinical trial of i...a. The trial showed that oral VA106483 was success...-diuretic effect in patients, as determined by,in...
Breaking Medicine Technology:deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled 2MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3AutoImmune Inc Reports 2008 Fourth Quarter and Year End Financial Results 11016 1AutoImmune Inc Reports 2008 Fourth Quarter and Year End Financial Results 11016 2AutoImmune Inc Reports 2008 Fourth Quarter and Year End Financial Results 11016 3AutoImmune Inc Reports 2008 Fourth Quarter and Year End Financial Results 11016 4Breast Cancer Awareness Event Including Free Educational Seminars 39635 1Breast Cancer Awareness Event Including Free Educational Seminars 39635 2Cardiac imaging highlighted at Biennial ICNC 9 39632 1Cardiac imaging highlighted at Biennial ICNC 9 39632 2Cardiac imaging highlighted at Biennial ICNC 9 39632 3Cardiac imaging highlighted at Biennial ICNC 9 39632 4Alzheimers Disease Neuroimaging Initiative announces completion of genome wide analysis 39629 1Alzheimers Disease Neuroimaging Initiative announces completion of genome wide analysis 39629 2Alzheimers Disease Neuroimaging Initiative announces completion of genome wide analysis 39629 3... and NUTLEY, N.J., April 23, 2007 /PRNewswire/ --,...if a renal anemia,treatment administered once ever... of epoetin alfa, hemodialysis centers may save an... per year per 100,patients. These data, from a mul...t in hemodialysis patients, were presented today,d...
...olo., April 24, 2007 /PRNewswire/ -- Accera Inc.,a...b study of its,lead compound AC-1202 in Alzheimer,...ting of the American Academy of Neurology (AAN) in...ercent of the,program, the data will also be featu..., Accera,s vice president of clinical development ...
Other Medicine Technology:Prospective Model Outlined Potential Time and Cost Savings of,Once-Monthly Anemia Treatment 2Prospective Model Outlined Potential Time and Cost Savings of,Once-Monthly Anemia Treatment 3Accera, Inc. to Present Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting 2